Immunotherapy as a treatment strategy in advanced stage and recurrent endometrial cancer: review of current phase III immunotherapy clinical trials

Ramez N Eskander; Matthew A Powell

doi:10.1177/17588359211001199

Immunotherapy as a treatment strategy in advanced stage and recurrent endometrial cancer: review of current phase III immunotherapy clinical trials

Ther Adv Med Oncol. 2021 Mar 16:13:17588359211001199. doi: 10.1177/17588359211001199. eCollection 2021.

Authors

Ramez N Eskander¹, Matthew A Powell²

Affiliations

¹ Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Gynecologic Oncology, University of California San Diego Moores Cancer Center, 3855 Health Sciences Drive, La Jolla, CA 92093, USA.
² Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, St. Louis, MO, USA.

Abstract

The treatment of advanced stage, metastatic or recurrent endometrial cancer remains a clinically difficult scenario. Although combination carboplatin and paclitaxel is an effective standard-of-care regimen, alternate strategies have shown promise, particularly in biomarker select populations. In an effort to improve oncologic outcomes, investigators are exploring novel immunotherapy combinations. In this review, we discuss the clinical rationale and design of current phase III immuno-oncology clinical trials in patients with advanced stage or recurrent endometrial cancer.

Keywords: antiangiogenic therapy; chemotherapy; combination therapy; endometrial cancer; immune checkpoint inhibition; immunotherapy; tumor mutational burden.

Publication types

Review